Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 41

1.

Radiation therapy as a bridging strategy for CAR T cell therapy with axicabtagene ciloleucel in diffuse large B-cell lymphoma.

Sim AJ, Jain MD, Figura N, Chavez JC, Shah BD, Khimani F, Lazarayan A, Krivenko G, Davila ML, Liu HD, Falchook AD, Dahiya S, Rapoport AP, Kim SU, Locke FL, Robinson TJ.

Int J Radiat Oncol Biol Phys. 2019 Jun 5. pii: S0360-3016(19)30819-3. doi: 10.1016/j.ijrobp.2019.05.065. [Epub ahead of print]

PMID:
31175906
2.

Disruption of a self-amplifying catecholamine loop reduces cytokine release syndrome.

Staedtke V, Bai RY, Kim K, Darvas M, Davila ML, Riggins GJ, Rothman PB, Papadopoulos N, Kinzler KW, Vogelstein B, Zhou S.

Nature. 2018 Dec;564(7735):273-277. doi: 10.1038/s41586-018-0774-y. Epub 2018 Dec 12.

3.

Distinct Regulation of Th17 and Th1 Cell Differentiation by Glutaminase-Dependent Metabolism.

Johnson MO, Wolf MM, Madden MZ, Andrejeva G, Sugiura A, Contreras DC, Maseda D, Liberti MV, Paz K, Kishton RJ, Johnson ME, de Cubas AA, Wu P, Li G, Zhang Y, Newcomb DC, Wells AD, Restifo NP, Rathmell WK, Locasale JW, Davila ML, Blazar BR, Rathmell JC.

Cell. 2018 Dec 13;175(7):1780-1795.e19. doi: 10.1016/j.cell.2018.10.001. Epub 2018 Nov 1.

PMID:
30392958
4.

4-1BB enhancement of CAR T function requires NF-κB and TRAFs.

Li G, Boucher JC, Kotani H, Park K, Zhang Y, Shrestha B, Wang X, Guan L, Beatty N, Abate-Daga D, Davila ML.

JCI Insight. 2018 Sep 20;3(18). pii: 121322. doi: 10.1172/jci.insight.121322. eCollection 2018 Sep 20.

5.

Screening Clinical Cell Products for Replication Competent Retrovirus: The National Gene Vector Biorepository Experience.

Cornetta K, Duffy L, Feldman SA, Mackall CL, Davila ML, Curran KJ, Junghans RP, Tang JY, Kochenderfer JN, O'Cearbhaill R, Archer G, Kiem HP, Shah NN, Delbrook C, Kaplan R, Brentjens RJ, Rivière I, Sadelain M, Rosenberg SA.

Mol Ther Methods Clin Dev. 2018 Aug 17;10:371-378. doi: 10.1016/j.omtm.2018.08.006. eCollection 2018 Sep 21.

6.

CAR T cells find strength in polyfunction.

Davila ML.

Blood. 2018 Aug 23;132(8):769-770. doi: 10.1182/blood-2018-06-858712. No abstract available.

PMID:
30139827
7.

CAR T cells, immunologic and cellular therapies in hematologic malignancies.

Brentjens R, Davila ML.

Best Pract Res Clin Haematol. 2018 Jun;31(2):115-116. doi: 10.1016/j.beha.2018.05.001. Epub 2018 May 18. No abstract available.

PMID:
29909911
8.

VDJServer: A Cloud-Based Analysis Portal and Data Commons for Immune Repertoire Sequences and Rearrangements.

Christley S, Scarborough W, Salinas E, Rounds WH, Toby IT, Fonner JM, Levin MK, Kim M, Mock SA, Jordan C, Ostmeyer J, Buntzman A, Rubelt F, Davila ML, Monson NL, Scheuermann RH, Cowell LG.

Front Immunol. 2018 May 8;9:976. doi: 10.3389/fimmu.2018.00976. eCollection 2018.

9.

NKG2D-based chimeric antigen receptor therapy induced remission in a relapsed/refractory acute myeloid leukemia patient.

Sallman DA, Brayer J, Sagatys EM, Lonez C, Breman E, Agaugué S, Verma B, Gilham DE, Lehmann FF, Davila ML.

Haematologica. 2018 Sep;103(9):e424-e426. doi: 10.3324/haematol.2017.186742. Epub 2018 Apr 27. No abstract available.

10.

Study protocol for THINK: a multinational open-label phase I study to assess the safety and clinical activity of multiple administrations of NKR-2 in patients with different metastatic tumour types.

Lonez C, Verma B, Hendlisz A, Aftimos P, Awada A, Van Den Neste E, Catala G, Machiels JH, Piette F, Brayer JB, Sallman DA, Kerre T, Odunsi K, Davila ML, Gilham DE, Lehmann FF.

BMJ Open. 2017 Nov 12;7(11):e017075. doi: 10.1136/bmjopen-2017-017075.

11.

Concurrent therapy of chronic lymphocytic leukemia and Philadelphia chromosome-positive acute lymphoblastic leukemia utilizing CD19-targeted CAR T-cells.

Geyer MB, Manjunath SH, Evans AG, Park JH, Davila ML, Cutler CS, Wang X, Wang Y, Senechal B, Rivière I, Sadelain M, Liesveld JL, Brentjens RJ.

Leuk Lymphoma. 2018 Jul;59(7):1717-1721. doi: 10.1080/10428194.2017.1390237. Epub 2017 Oct 18. No abstract available.

PMID:
29043880
12.

Concise Review: Emerging Principles from the Clinical Application of Chimeric Antigen Receptor T Cell Therapies for B Cell Malignancies.

Jain MD, Davila ML.

Stem Cells. 2018 Jan;36(1):36-44. doi: 10.1002/stem.2715. Epub 2017 Oct 25. Review.

13.

Is Disease-Specific Immunotherapy a Potential Reality for MDS?

Sallman DA, Davila ML.

Clin Lymphoma Myeloma Leuk. 2017 Jul;17S:S26-S30. doi: 10.1016/j.clml.2017.03.292. Review.

PMID:
28760299
14.

Regulatory challenges and considerations for the clinical application of CAR-T cell anti-cancer therapy.

Locke FL, Davila ML.

Expert Opin Biol Ther. 2017 Jun;17(6):659-661. doi: 10.1080/14712598.2017.1322953. No abstract available.

PMID:
28454503
15.

Donor CD19 CAR T cells exert potent graft-versus-lymphoma activity with diminished graft-versus-host activity.

Ghosh A, Smith M, James SE, Davila ML, Velardi E, Argyropoulos KV, Gunset G, Perna F, Kreines FM, Levy ER, Lieberman S, Jay HV, Tuckett AZ, Zakrzewski JL, Tan L, Young LF, Takvorian K, Dudakov JA, Jenq RR, Hanash AM, Motta AC, Murphy GF, Liu C, Schietinger A, Sadelain M, van den Brink MR.

Nat Med. 2017 Feb;23(2):242-249. doi: 10.1038/nm.4258. Epub 2017 Jan 9.

16.
17.
18.

At The Bedside: Clinical review of chimeric antigen receptor (CAR) T cell therapy for B cell malignancies.

Oluwole OO, Davila ML.

J Leukoc Biol. 2016 Dec;100(6):1265-1272. Epub 2016 Jun 27. Review.

PMID:
27354412
19.

Biology and clinical application of CAR T cells for B cell malignancies.

Davila ML, Sadelain M.

Int J Hematol. 2016 Jul;104(1):6-17. doi: 10.1007/s12185-016-2039-6. Epub 2016 Jun 4. Review.

20.

CAR models: next-generation CAR modifications for enhanced T-cell function.

Abate-Daga D, Davila ML.

Mol Ther Oncolytics. 2016 May 18;3:16014. doi: 10.1038/mto.2016.14. eCollection 2016. Review.

21.

Outcome of EMR as an alternative to surgery in patients with complex colon polyps.

Raju GS, Lum PJ, Ross WA, Thirumurthi S, Miller E, Lynch PM, Lee JH, Bhutani MS, Shafi MA, Weston BR, Pande M, Bresalier RS, Rashid A, Mishra L, Davila ML, Stroehlein JR.

Gastrointest Endosc. 2016 Aug;84(2):315-25. doi: 10.1016/j.gie.2016.01.067. Epub 2016 Feb 6.

22.

CD19-Targeted T Cells for Hematologic Malignancies: Clinical Experience to Date.

Davila ML, Sauter C, Brentjens R.

Cancer J. 2015 Nov-Dec;21(6):470-4. doi: 10.1097/PPO.0000000000000153. Review.

23.

Natural language processing as an alternative to manual reporting of colonoscopy quality metrics.

Raju GS, Lum PJ, Slack RS, Thirumurthi S, Lynch PM, Miller E, Weston BR, Davila ML, Bhutani MS, Shafi MA, Bresalier RS, Dekovich AA, Lee JH, Guha S, Pande M, Blechacz B, Rashid A, Routbort M, Shuttlesworth G, Mishra L, Stroehlein JR, Ross WA.

Gastrointest Endosc. 2015 Sep;82(3):512-9. doi: 10.1016/j.gie.2015.01.049. Epub 2015 Apr 22.

24.

Using gene therapy to manipulate the immune system in the fight against B-cell leukemias.

Bouhassira DC, Thompson JJ, Davila ML.

Expert Opin Biol Ther. 2015 Mar;15(3):403-16. doi: 10.1517/14712598.2015.1014792. Epub 2015 Feb 9. Review.

25.

CARs Move To the Fast Lane.

Davila ML, Papapetrou EP.

Mol Ther. 2014 Mar;22(3):477-478. doi: 10.1038/mt.2014.8. Epub 2016 Dec 6. No abstract available.

26.

Efficacy and toxicity management of 19-28z CAR T cell therapy in B cell acute lymphoblastic leukemia.

Davila ML, Riviere I, Wang X, Bartido S, Park J, Curran K, Chung SS, Stefanski J, Borquez-Ojeda O, Olszewska M, Qu J, Wasielewska T, He Q, Fink M, Shinglot H, Youssif M, Satter M, Wang Y, Hosey J, Quintanilla H, Halton E, Bernal Y, Bouhassira DC, Arcila ME, Gonen M, Roboz GJ, Maslak P, Douer D, Frattini MG, Giralt S, Sadelain M, Brentjens R.

Sci Transl Med. 2014 Feb 19;6(224):224ra25. doi: 10.1126/scitranslmed.3008226.

27.

Chimeric antigen receptors for the adoptive T cell therapy of hematologic malignancies.

Davila ML, Bouhassira DC, Park JH, Curran KJ, Smith EL, Pegram HJ, Brentjens R.

Int J Hematol. 2014 Apr;99(4):361-71. doi: 10.1007/s12185-013-1479-5. Epub 2013 Dec 6. Review.

28.

Endoscopic management of Barrett's esophagus with high-grade dysplasia and early-stage esophageal adenocarcinoma.

Davila ML, Hofstetter WL.

Thorac Surg Clin. 2013 Nov;23(4):479-89. doi: 10.1016/j.thorsurg.2013.07.010. Review.

PMID:
24199698
29.

CD19 CAR-targeted T cells induce long-term remission and B Cell Aplasia in an immunocompetent mouse model of B cell acute lymphoblastic leukemia.

Davila ML, Kloss CC, Gunset G, Sadelain M.

PLoS One. 2013 Apr 9;8(4):e61338. doi: 10.1371/journal.pone.0061338. Print 2013.

30.

Chimeric antigen receptor therapy for chronic lymphocytic leukemia: what are the challenges?

Davila ML, Brentjens R.

Hematol Oncol Clin North Am. 2013 Apr;27(2):341-53. doi: 10.1016/j.hoc.2012.12.004. Review.

31.

CD19-targeted T cells rapidly induce molecular remissions in adults with chemotherapy-refractory acute lymphoblastic leukemia.

Brentjens RJ, Davila ML, Riviere I, Park J, Wang X, Cowell LG, Bartido S, Stefanski J, Taylor C, Olszewska M, Borquez-Ojeda O, Qu J, Wasielewska T, He Q, Bernal Y, Rijo IV, Hedvat C, Kobos R, Curran K, Steinherz P, Jurcic J, Rosenblat T, Maslak P, Frattini M, Sadelain M.

Sci Transl Med. 2013 Mar 20;5(177):177ra38. doi: 10.1126/scitranslmed.3005930.

32.

How do CARs work?: Early insights from recent clinical studies targeting CD19.

Davila ML, Brentjens R, Wang X, Rivière I, Sadelain M.

Oncoimmunology. 2012 Dec 1;1(9):1577-1583.

33.

Safety and persistence of adoptively transferred autologous CD19-targeted T cells in patients with relapsed or chemotherapy refractory B-cell leukemias.

Brentjens RJ, Rivière I, Park JH, Davila ML, Wang X, Stefanski J, Taylor C, Yeh R, Bartido S, Borquez-Ojeda O, Olszewska M, Bernal Y, Pegram H, Przybylowski M, Hollyman D, Usachenko Y, Pirraglia D, Hosey J, Santos E, Halton E, Maslak P, Scheinberg D, Jurcic J, Heaney M, Heller G, Frattini M, Sadelain M.

Blood. 2011 Nov 3;118(18):4817-28. doi: 10.1182/blood-2011-04-348540. Epub 2011 Aug 17.

34.

Optimum palliation of inoperable hilar cholangiocarcinoma: comparative assessment of the efficacy of plastic and self-expanding metal stents.

Raju RP, Jaganmohan SR, Ross WA, Davila ML, Javle M, Raju GS, Lee JH.

Dig Dis Sci. 2011 May;56(5):1557-64. doi: 10.1007/s10620-010-1550-5. Epub 2011 Jan 11.

PMID:
21222156
35.

Photodynamic therapy.

Davila ML.

Gastrointest Endosc Clin N Am. 2011 Jan;21(1):67-79. doi: 10.1016/j.giec.2010.09.002. Review.

PMID:
21112498
36.

The demise of air insufflation and the rise of the warm water infusion method.

Davila ML, Davila RE.

Gastrointest Endosc. 2009 Sep;70(3):511-4. doi: 10.1016/j.gie.2009.05.022. No abstract available.

PMID:
19699980
37.

Neutropenic enterocolitis: current issues in diagnosis and management.

Davila ML.

Curr Infect Dis Rep. 2007 Mar;9(2):116-20.

PMID:
17324348
38.

Neutropenic enterocolitis.

Davila ML.

Curr Treat Options Gastroenterol. 2006 Jun;9(3):249-55.

PMID:
16901388
39.

Neutropenic enterocolitis.

Davila ML.

Curr Opin Gastroenterol. 2006 Jan;22(1):44-7. Review.

PMID:
16319675
40.

[Comparison of sevoflurane and propofol in the maintenance of and recovery from anesthesia].

Rodiño S, Rama P, Pensado A, Dávila ML, Molins N, Fraga M.

Rev Esp Anestesiol Reanim. 1999 Dec;46(10):427-32. Spanish.

PMID:
10670263
41.

[Rhabdomyolysis and crush syndrome: a diagnosis to consider in multiple trauma patients].

Pensado A, Domínguez L, Ferreira TA, Dávila ML, López-Alvarez S, Molins N.

Rev Esp Anestesiol Reanim. 1997 Dec;44(10):416-7. Spanish. No abstract available.

PMID:
9494373

Supplemental Content

Loading ...
Support Center